BORA PHARMACEUTICALS LTD (6472) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BORA PHARMACEUTICALS LTD (6472) has a cash flow conversion efficiency ratio of 0.034x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$568.46 Million ≈ $17.91 Million USD) by net assets (NT$16.63 Billion ≈ $523.89 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BORA PHARMACEUTICALS LTD (6472) balance sheet quality index to measure how much of total assets are equity-financed.
BORA PHARMACEUTICALS LTD - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how BORA PHARMACEUTICALS LTD's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of BORA PHARMACEUTICALS LTD to evaluate the quality of earnings relative to operating cash generation.
BORA PHARMACEUTICALS LTD Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BORA PHARMACEUTICALS LTD ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Seojin System Co.Ltd
KQ:178320
|
-0.029x |
|
Browave
TWO:3163
|
0.043x |
|
Israel Corp
TA:ILCO
|
0.038x |
|
Hubei Zhongyi Science Technology Co. Ltd.
SHE:301150
|
0.004x |
|
Intershop Holding AG
SW:ISN
|
0.014x |
|
Transmissora Aliança de Energia Elétrica S.A
SA:TAEE3
|
0.086x |
|
Sanoma Oyj
HE:SANOMA
|
0.237x |
|
Luxin Venture Capital Group Co Ltd
SHG:600783
|
0.009x |
Annual Cash Flow Conversion Efficiency for BORA PHARMACEUTICALS LTD (2019–2025)
The table below shows the annual cash flow conversion efficiency of BORA PHARMACEUTICALS LTD from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see market value of BORA PHARMACEUTICALS LTD.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | NT$17.47 Billion ≈ $550.47 Million |
NT$4.24 Billion ≈ $133.64 Million |
0.243x | +271.59% |
| 2024-09-30 | NT$15.01 Billion ≈ $472.95 Million |
NT$980.81 Million ≈ $30.90 Million |
0.065x | -83.34% |
| 2023-09-30 | NT$11.77 Billion ≈ $370.69 Million |
NT$4.61 Billion ≈ $145.36 Million |
0.392x | +0.28% |
| 2022-09-30 | NT$5.14 Billion ≈ $161.95 Million |
NT$2.01 Billion ≈ $63.33 Million |
0.391x | -0.32% |
| 2021-09-30 | NT$3.15 Billion ≈ $99.32 Million |
NT$1.24 Billion ≈ $38.96 Million |
0.392x | +443.81% |
| 2020-09-30 | NT$2.46 Billion ≈ $77.65 Million |
NT$177.79 Million ≈ $5.60 Million |
0.072x | -48.53% |
| 2019-09-30 | NT$1.65 Billion ≈ $52.10 Million |
NT$231.77 Million ≈ $7.30 Million |
0.140x | -- |
About BORA PHARMACEUTICALS LTD
Bora Pharmaceuticals Co., LTD. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services fo… Read more